This clinical reference provides authoritative, evidence-based medical information for healthcare professionals. It is intended for educational purposes and to support clinical decision-making. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment in the context of individual patient circumstances, local guidelines, and the latest evidence. Dosages and recommendations should be verified with current prescribing information and local protocols.

---

Stages Of Tb Meningitis

Overview

• Definition: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis (TB), caused by Mycobacterium tuberculosis affecting the meninges (membranes surrounding the brain and spinal cord) and brain parenchyma. It is a subacute or chronic inflammatory process leading to neurological deficits, hydrocephalus, and vasculitis if untreated.
• Epidemiology:
  • Accounts for approximately 5-10% of all extrapulmonary TB cases.
  • More common in immunocompromised individuals (e.g., HIV-infected persons), young children (under 5 years old), and those from regions with high TB prevalence.
  • High mortality rates, especially in advanced stages, ranging from 20-50%, and up to 70% in HIV co-infected individuals. Significant morbidity (neurological sequelae) is also common among survivors.
• Classification: TBM is classically staged according to the British Medical Research Council (BMRC) criteria, which correlates with prognosis and guides treatment intensity, particularly corticosteroid use:
  • Stage I (Early): Conscious and rational, no focal neurological signs, no hydrocephalus or cranial nerve palsies. Characterized by non-specific symptoms like fever, headache, malaise.
  • Stage II (Moderate): Glasgow Coma Scale (GCS) 11-14 (or altered mentation), presence of focal neurological deficits (e.g., cranial nerve palsies, monoplegia, hemiplegia) but without stupor or severe paresis. Signs of meningeal irritation may be present.
  • Stage III (Advanced/Late): GCS 10 or less (stupor or coma), severe focal neurological deficits (e.g., dense hemiplegia, paraplegia, decerebrate/decorticate posturing), or hydrocephalus with signs of raised intracranial pressure (ICP).

Pathophysiology

• Mechanism:
  1. Initial Infection: Primary M. tuberculosis infection typically occurs in the lungs, leading to bacteremia and hematogenous dissemination.
  2. Meningeal Seeding: Bacilli cross the blood-brain barrier and seed the brain parenchyma or meninges, forming small, subpial or subependymal caseous foci (Rich foci).
  3. Rupture of Rich Foci: After a variable latent period (weeks to years), rupture of a Rich focus into the subarachnoid space leads to the release of mycobacterial antigens and viable bacilli.
  4. Inflammatory Response: This triggers a robust inflammatory response in the subarachnoid space, particularly at the base of the brain. An exudate rich in lymphocytes, plasma cells, and macrophages forms, obstructing cerebrospinal fluid (CSF) flow and encasing cranial nerves and blood vessels.
  5. Complications:
     • Hydrocephalus: Obstruction of CSF pathways (aqueduct of Sylvius, basal cisterns) by inflammatory exudates.
     • Vasculitis: Inflammation of blood vessels (arteritis, phlebitis), especially the perforating arteries supplying the basal ganglia and internal capsule, leading to cerebral infarction.
     • Tuberculomas: Granulomatous masses within the brain parenchyma.
     • Arachnoiditis: Inflammation and fibrosis of the arachnoid mater.
• Risk Factors:
  • HIV infection (most significant risk factor, increasing risk by 100-fold)
  • Other immunocompromised states (e.g., organ transplant recipients, TNF-alpha inhibitor therapy, prolonged corticosteroid use, malignancy, diabetes mellitus, chronic kidney disease)
  • Young age (<5 years old due to immature immune system and developing blood-brain barrier)
  • Malnutrition
  • Alcoholism and substance abuse
  • Contact with active TB cases
  • End-stage renal disease
  • Geographic origin from high TB prevalence areas
• Protective Factors:
  • BCG vaccination (confers some protection, especially against severe forms in children, but variable efficacy against TBM)
  • Absence of immunocompromising conditions
  • Effective public health programs for TB control and early treatment of latent TB infection

Clinical Presentation

Signs and Symptoms

The presentation of TBM is often insidious, evolving over days to weeks. The staging guides clinical assessment.

• Cardinal Features:
  • Headache: Most common symptom, often progressive, persistent, and severe.
  • Fever: Low-grade, persistent, often worse in the evening.
  • Altered mental status: Ranging from lethargy and confusion to stupor and coma, correlating with disease progression (Stage I to III).
  • Meningismus: Neck stiffness, positive Kernig's and Brudzinski's signs (less prominent in early stages, especially in young children or immunocompromised patients).
• Early Signs (Predominantly Stage I):
  • Non-specific prodrome: Malaise, fatigue, anorexia, weight loss.
  • Low-grade fever, often persistent.
  • Intermittent headache.
  • Personality changes, irritability in children.
  • Mild confusion or apathy.
• Advanced Signs (Predominantly Stage II and III):
  • Worsening headache and fever.
  • Altered consciousness: Drowsiness, confusion, disorientation, progressing to stupor or coma.
  • Focal neurological deficits:
    • Cranial nerve palsies (most commonly abducens (VI), facial (VII), oculomotor (III) due to basal exudates).
    • Hemiparesis/hemiplegia due to vasculitis and infarction.
    • Involuntary movements, tremors.
    • Ataxia.
  • Signs of increased ICP: Papilledema, vomiting (especially projectile), bradycardia, hypertension (Cushing's triad – late sign).
  • Seizures: Common, especially in children.
  • Spinal involvement: Radiculopathy, myelopathy.
• Atypical Presentations:
  • Fulminant course: Rapid progression, mimicking acute bacterial meningitis, especially in immunocompromised patients.
  • Cerebritis or tuberculoma presentation: Predominant features of focal neurological deficits without prominent meningeal signs.
  • Spinal TB meningitis: Predominantly spinal symptoms (back pain, radicular pain, weakness, sphincter dysfunction).
  • Absence of fever: May occur in elderly or immunocompromised patients.

Physical Examination

• Inspection:
  • Level of consciousness (using GCS, correlates with BMRC staging).
  • Nutritional status (e.g., signs of cachexia).
  • Respiratory pattern (may indicate brainstem involvement).
  • Pupillary size, symmetry, and reactivity (check for signs of herniation).
  • Signs of associated systemic TB (e.g., lymphadenopathy, pleural effusion, ascites, skin lesions).
• Palpation:
  • Neck stiffness (meningismus).
  • Hydrocephalus (in infants: tense fontanelle, increased head circumference).
• Special Tests:
  • Neurological examination:
    • Cranial nerves: Assess for palsies (e.g., VI nerve palsy causing lateral rectus weakness, III nerve palsy causing ptosis, dilated pupil, eye deviation).
    • Motor system: Muscle strength, tone, reflexes (may show signs of hemiparesis, spasticity, hyperreflexia).
    • Sensory system: Diminished sensation in affected areas.
    • Coordination and gait: Ataxia.
  • Meningeal signs:
    • Kernig's sign: Pain and hamstring spasm on extending the knee with hip flexed.
    • Brudzinski's sign: Involuntary flexion of hips and knees upon passive neck flexion.
  • Fundoscopy: Check for papilledema (indicates raised ICP), choroidal tubercles (pathognomonic but rare, seen in 1-2% of cases).

Diagnostic Approach

TBM diagnosis is challenging due to insidious onset, non-specific symptoms, and difficulty isolating the organism. Early diagnosis is crucial for improving outcomes.

History Taking

• Key Questions:
  • Duration and progression of symptoms (headache, fever, mental status changes).
  • Any focal neurological deficits (weakness, vision changes, speech difficulty).
  • History of TB exposure (household contact, living in endemic area).
  • Past medical history: Prior TB, HIV status, other immunosuppressive conditions, diabetes, alcoholism.
  • Travel history.
  • BCG vaccination status.
  • Symptoms of systemic TB (cough, weight loss, night sweats).
• Red Flags:
  • Rapid decline in GCS.
  • New onset focal neurological deficits (especially hemiparesis, cranial nerve palsies).
  • Signs of increased ICP (projectile vomiting, papilledema, Cushing's triad).
  • Seizures.
  • These suggest progression to Stage II or III and necessitate urgent neuroimaging and lumbar puncture.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): May show mild anemia, normal or mildly elevated white blood cell count (WBC), often lymphocytosis.
  • Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP): Often elevated but non-specific.
  • HIV testing: Essential in all TBM suspects.
  • Lumbar Puncture (LP) and Cerebrospinal Fluid (CSF) Analysis: The cornerstone of TBM diagnosis.
    • Opening pressure: Often elevated (>200 mm H2O), especially in later stages with hydrocephalus.
    • Appearance: Usually clear or xanthochromic (yellowish due to high protein), but can be turbid if very high cell count.
    • Cell count: Typically 10-500 cells/µL, predominantly lymphocytes (lymphocytic pleocytosis >80%). Early in disease, polymorphonuclear leukocytes (neutrophils) may predominate, especially in children or HIV-coinfected.
    • Protein: Markedly elevated, usually >1 g/L (normal <0.45 g/L), sometimes >5 g/L. This is a key feature.
    • Glucose: Low, typically <40 mg/dL (normal >60 mg/dL, or CSF:blood glucose ratio <0.5).
    • CSF Culture for M. tuberculosis: Gold standard, but slow (3-6 weeks) and low sensitivity (30-60%), even with large CSF volumes. Multiple LPs can increase yield.
    • CSF Acid-Fast Bacilli (AFB) smear: Very low sensitivity (10-20%), but highly specific if positive. Requires at least 10^4 bacilli/mL.
• Confirmatory:
  • Nucleic Acid Amplification Tests (NAATs):
    • Xpert MTB/RIF: Endorsed by WHO, highly sensitive (60-80% for TBM) and specific for M. tuberculosis complex, and simultaneously detects rifampicin resistance mutations. Rapid results (within 2 hours). First-line molecular test for CSF.
    • TB-LAMP (Loop-mediated Isothermal Amplification): Alternative rapid molecular test, good sensitivity/specificity.
    • Line Probe Assay (LPA): Detects drug resistance mutations to isoniazid and rifampicin (first-line) or fluoroquinolones and injectable agents (second-line). Requires positive culture or concentrated smear.
  • CSF ADA (Adenosine Deaminase): Elevated levels (>8-10 U/L) can support diagnosis but are not specific for TBM (can be elevated in other conditions like bacterial meningitis, sarcoidosis). Sensitivity and specificity vary.
  • TB-specific interferon-gamma release assays (IGRAs - e.g., T-SPOT.TB, QuantiFERON-TB Gold Plus): Positive in patients with TB infection but do not distinguish between latent infection and active disease, nor do they confirm TBM specifically. Less useful for CSF diagnosis, primarily for systemic infection.
  • Biopsy: In rare cases where diagnosis is unclear and a focal lesion is present, brain biopsy may be considered, but usually avoided due to invasiveness.
• Monitoring:
  • Repeat LP: Rarely indicated for monitoring treatment response, but may be performed if clinical deterioration or suspicion of drug resistance warrants repeat CSF analysis and culture/NAAT.
  • ESR/CRP: Can be monitored, but not definitive for treatment response.
  • Serial imaging: To monitor resolution of hydrocephalus, tuberculomas, or infarcts.

Imaging

• Recommended:
  • Computed Tomography (CT) Brain with Contrast: Often the initial imaging modality due to availability and speed, especially in emergency settings to rule out mass lesions or hydrocephalus.
    • Key findings:
      • Basal meningeal enhancement: Most characteristic finding, but may be subtle or absent in early stages (Stage I). Best seen in the cisterns around the brainstem and Sylvian fissures.
      • Hydrocephalus: Communicating or obstructive (common in Stage II/III).
      • Cerebral infarcts: Due to vasculitis, often in basal ganglia or internal capsule, may be bilateral.
      • Tuberculomas: Ring-enhancing lesions, variable size, solitary or multiple, often near the basal cisterns or sulci.
      • Edema: Periventricular or focal.
  • Magnetic Resonance Imaging (MRI) Brain with Contrast: Superior to CT for demonstrating subtle meningeal enhancement, parenchymal lesions, and assessing vascular involvement and spinal cord lesions. It is the preferred imaging modality.
    • Key findings: Similar to CT but with better resolution. FLAIR sequences show inflammatory exudates. MR angiography (MRA) or venography (MRV) can demonstrate vasculitis or venous thrombosis.
• Advanced:
  • MR Spectroscopy (MRS): May show elevated lipid peaks, diminished N-acetylaspartate, and elevated choline/creatine ratios in tuberculomas or areas of inflammation, but not routinely used.
  • Digital Subtraction Angiography (DSA): Rarely performed, but can show vessel narrowing or occlusion in severe vasculitis.

Management

TBM is a medical emergency requiring prompt initiation of anti-TB chemotherapy and corticosteroids. Treatment should be initiated empirically if clinical suspicion is high, without waiting for microbiological confirmation.

Acute Management

• Immediate:
  • Stabilization: Secure airway, breathing, circulation (ABCs). Assess GCS and neurological status.
  • Lumbar Puncture: Perform urgently if no contraindications (e.g., signs of brain herniation, focal neurological deficits and hydrocephalus on imaging, severe coagulopathy).
  • Empiric anti-TB therapy: Start immediately after LP, or even before if LP is delayed due to contraindications or need for imaging.
  • Corticosteroids: Start concomitant with anti-TB drugs.
• Stabilization:
  • Control of intracranial pressure (ICP):
    • Head elevation (30 degrees).
    • Mannitol (0.25-1 g/kg IV over 20-30 min) or hypertonic saline (3% NaCl) for acute ICP elevation.
    • Ventricular drain (EVD) or ventriculoperitoneal (VP) shunt placement for severe hydrocephalus with clinical deterioration or sustained elevated ICP.
  • Seizure management: Administer antiepileptics (e.g., levetiracetam, phenytoin) if seizures occur or if there's a high risk.
  • Fluid and electrolyte balance: Avoid overhydration which can worsen cerebral edema. Monitor serum sodium closely (SIADH can occur).
  • Nutritional support: Important due to prolonged illness.
• Emergency:
  • Neurosurgical consultation: For hydrocephalus requiring CSF diversion (EVD, VP shunt).
  • Management of herniation syndromes: Rapid ICP reduction with mannitol/hypertonic saline, hyperventilation, and emergent CSF drainage if shunt is already in place or EVD can be inserted.

Chronic Management

• Pharmacological:
  • Anti-tuberculous chemotherapy: Standard first-line drugs for TBM are typically given for a prolonged duration.
    • Intensive Phase: 2 months of daily rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) (RIPE regimen).
      • Rifampicin: 10 mg/kg (max 600 mg daily). Potent inducer of cytochrome P450 enzymes.
      • Isoniazid: 5 mg/kg (max 300 mg daily). Administer with pyridoxine (vitamin B6, 10-25 mg daily) to prevent peripheral neuropathy.
      • Pyrazinamide: 20-30 mg/kg (max 2 g daily).
      • Ethambutol: 15-25 mg/kg (max 1.6 g daily). Monitor for ocular toxicity (optic neuritis).
    • Continuation Phase: 7-10 months of daily rifampicin and isoniazid. Total duration is typically 9-12 months. Some guidelines advocate for 12 months, especially for advanced stages or HIV co-infection.
    • Drug-resistant TB: If drug resistance is suspected or confirmed (e.g., RIF resistance by Xpert), treatment regimen must be adapted based on drug susceptibility testing (DST). This often involves fluoroquinolones (e.g., levofloxacin, moxifloxacin), bedaquiline, linezolid, and other second-line drugs for much longer durations.
  • Corticosteroids (Dexamethasone): Essential adjunct therapy for all stages of TBM, significantly reduces mortality and neurological sequelae.
    • Dosing:
      • Adults (Standard):
        • Stage I: 0.3 mg/kg/day IV for 1 week, then 0.2 mg/kg/day for 1 week, 0.1 mg/kg/day for 2 weeks, then oral taper over 4 weeks.
        • Stage II/III: 0.4 mg/kg/day IV for 1 week, then 0.3 mg/kg/day for 1 week, 0.2 mg/kg/day for 1 week, 0.1 mg/kg/day for 1 week, then oral taper over 4 weeks.
      • Pediatrics:
        • Stage I: 0.2 mg/kg/day IV/PO for 4 weeks, then taper over 2 weeks.
        • Stage II/III: 0.4 mg/kg/day IV/PO for 4 weeks, then taper over 2 weeks.
      • Note: Regimens vary slightly, but generally involve high-dose IV for 2-4 weeks, followed by a gradual oral taper over 4-6 weeks for a total of 6-8 weeks.
    • Rationale: Reduce inflammation, minimize basal exudate formation, reduce cerebral edema, and prevent complications like hydrocephalus and vasculitis.
• Non-pharmacological:
  • Nutritional support: Ensure adequate caloric and protein intake, especially if prolonged hospitalization.
  • Rehabilitation: Physiotherapy, occupational therapy, and speech therapy as needed for neurological deficits.
  • Psychological support: For patients and families coping with a severe chronic illness.
• Monitoring:
  • Clinical: Regular neurological assessments (GCS, focal signs), vital signs, fluid balance.
  • Biochemical: Liver function tests (LFTs) for hepatotoxicity (Isoniazid, Rifampicin, Pyrazinamide), renal function (Ethambutol), complete blood counts, electrolytes.
  • Ophthalmologic: Baseline and regular follow-up for visual acuity and color vision for ethambutol toxicity.
  • Audiometry: If aminoglycosides (e.g., streptomycin) are used for MDR-TB.
  • Drug levels: Therapeutic drug monitoring for anti-TB drugs is not routinely recommended but can be considered in non-responders, patients with severe malabsorption, or specific comorbidities (e.g., HIV with drug interactions).
  • Imaging: Follow-up CT/MRI scans to assess hydrocephalus, tuberculoma size, and response of basal exudates, especially if clinical deterioration or no improvement.

Treatment Algorithms

• First-Line (Drug-Susceptible TB):
  1. Suspect TBM based on clinical presentation and CSF findings.
  2. Perform LP and send CSF for Xpert MTB/RIF, culture, and routine analysis.
  3. Start empirical RIPE regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) daily.
  4. Concurrently start high-dose Dexamethasone (IV, then oral taper).
  5. If hydrocephalus is present and progressive/symptomatic, consider neurosurgical intervention (EVD/VP shunt).
  6. Duration: 2 months RIPE + Dexamethasone, followed by 7-10 months RH (total 9-12 months).
• Second-Line (Drug-Resistant TB, based on Xpert or DST):
  1. If Rifampicin resistance detected (or suspected): Initiate MDR-TB regimen based on local guidelines and DST results. This usually involves:
     • Fluoroquinolone (e.g., levofloxacin, moxifloxacin).
     • Linezolid.
     • Bedaquiline (if available and indicated).
     • Other agents based on resistance patterns (e.g., clofazimine, delamanid, cycloserine, high-dose isoniazid, ethionamide).
  2. Consult an infectious disease or TB specialist immediately.
  3. Duration: Treatment for MDR-TBM is typically much longer, often 18-24 months. Corticosteroids remain indicated.
• Refractory Cases:
  • Re-evaluation of diagnosis: Rule out alternative diagnoses, drug-resistant TB, or poor adherence.
  • Therapeutic Drug Monitoring (TDM): To ensure adequate drug levels.
  • Surgical intervention: For persistent or worsening hydrocephalus despite shunting, or for enlarging tuberculomas causing mass effect (surgical excision rarely indicated, but may be considered for large symptomatic lesions or for diagnostic purposes if unsure).
  • Adjunctive therapies: Consider new anti-TB agents if available and appropriate for resistance pattern.
  • Management of complications: Aggressive management of cerebral edema, seizures, and other neurological sequelae.

Complications

Complications are common and directly correlate with the stage of TBM at presentation and delay in diagnosis/treatment. - Common: * Hydrocephalus: Occurs in up to 80% of TBM patients, requiring CSF diversion in many. * Cranial nerve palsies: Most often abducens (VI), facial (VII), and oculomotor (III), due to entrapment in basal exudates. * Hyponatremia: Often due to SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) or cerebral salt wasting. * Seizures: Due to parenchymal irritation, vasculitis, or hydrocephalus. - Serious: * Cerebral infarction: Due to vasculitis, leading to permanent neurological deficits (e.g., hemiplegia, aphasia). * Spinal cord involvement: Tuberculous radiculomyelitis, leading to paraplegia, sensory loss, bladder/bowel dysfunction. * Optic atrophy and blindness: Due to direct compression of optic nerves or chiasm, or severe papilledema. * Communicating hydrocephalus: Can be difficult to manage surgically. * Drug-induced hepatotoxicity: From anti-TB drugs, requiring temporary cessation or regimen modification. * Adrenal insufficiency: Due to prolonged corticosteroid use, particularly upon rapid withdrawal. - Long-term: * Neurocognitive impairment: Memory deficits, learning difficulties, attention problems. * Persistent neurological deficits: Hemiparesis, visual impairment, hearing loss, ataxia. * Endocrine dysfunction: Hypopituitarism, diabetes insipidus (rare). * Epilepsy. * Chronic headaches. * Ventricular shunt malfunction or infection (if shunt placed).

Prognosis

Prognosis is highly dependent on the stage of disease at presentation, immune status, and promptness of appropriate therapy. - Factors: * Stage at presentation: Stage I has the best prognosis, Stage III the worst. * Age: Young children and elderly have worse outcomes. * HIV co-infection: Associated with higher mortality and poorer neurological outcomes. * Delay in diagnosis and treatment: Directly impacts mortality and morbidity. * Presence of complications: Hydrocephalus, cerebral infarcts, severe vasculitis, and drug resistance worsen prognosis. * Adherence to treatment: Crucial for cure and preventing relapse. - Survival: * Overall mortality: Ranges from 20% to 50% in adults, higher in children and HIV-positive patients. * Stage-specific mortality: * Stage I: <5% * Stage II: 10-30% * Stage III: 30-70% (or higher, especially in HIV-coinfected) - Quality of Life: * Significant neurological sequelae occur in 25-50% of survivors, leading to varying degrees of disability and impacting quality of life. * Mild residual deficits (e.g., mild cognitive impairment, gait disturbance) are common even in Stage I survivors. * Severe deficits (e.g., dense hemiplegia, blindness, severe cognitive impairment, persistent seizures) are more common in Stage II/III survivors.

Prevention

• Primary:
  • Early diagnosis and treatment of pulmonary TB: To prevent dissemination.
  • BCG vaccination: Recommended in high-burden countries, especially for children, to prevent severe forms of TB (including TBM and miliary TB). Efficacy against TBM in children is variable, estimated at 60-70%.
  • Infection control measures: In healthcare settings and congregate living facilities.
  • TB screening and preventive therapy for latent TB infection (LTBI): Especially for high-risk individuals (e.g., close contacts of active TB cases, immunocompromised patients).
• Secondary:
  • Early recognition and diagnosis of TBM: High index of suspicion for patients presenting with chronic headache, fever, and altered mental status, especially in endemic areas or with risk factors.
  • Prompt initiation of anti-TB therapy and corticosteroids: Once TBM is suspected.
• Tertiary:
  • Comprehensive management of TBM: Adherence to anti-TB regimen, corticosteroid tapering, and management of complications (e.g., neurosurgical intervention for hydrocephalus).
  • Rehabilitation: To minimize long-term neurological disability.

Special Populations

• Pediatric:
  • TBM is more common and often more severe in young children (<5 years).
  • Clinical presentation may be atypical (e.g., irritability, poor feeding, bulging fontanelle, seizures without clear meningeal signs).
  • CSF findings can be less typical, sometimes with neutrophil predominance initially.
  • Hydrocephalus is more common.
  • Drug dosages need careful weight-based calculation.
  • Higher risk of neurodevelopmental sequelae.
  • BCG vaccination is crucial.
• Geriatric:
  • Atypical presentation common (e.g., subtle mental status changes, less pronounced meningeal signs, absence of fever).
  • Co-morbidities and polypharmacy increase risk of drug interactions and toxicity.
  • Higher risk of adverse events from corticosteroids.
  • Increased mortality compared to younger adults.
• Pregnancy:
  • Diagnosis and management are similar, but careful consideration of drug safety during pregnancy is required.
  • First-line drugs (RIPE): All are generally considered safe during pregnancy. Pyridoxine supplementation (vitamin B6) is critical with isoniazid.
  • Corticosteroids: Dexamethasone is preferred over betamethasone due to less placental transfer.
  • Close monitoring for drug toxicity is essential.
• Comorbidities (e.g., HIV co-infection):
  • Most significant comorbidity.
  • Higher incidence, more rapid progression, higher mortality, and worse neurological outcomes.
  • Atypical CSF findings (e.g., higher cell count, more neutrophils, or normal cell count).
  • Challenges with drug interactions (e.g., rifampicin and antiretroviral therapy (ART)). ART should be initiated 2-8 weeks after starting anti-TB therapy to reduce the risk of IRIS (Immune Reconstitution Inflammatory Syndrome).
  • Higher risk of paradoxical IRIS presenting as worsening neurological symptoms or new tuberculomas.
  • Longer duration of anti-TB treatment (e.g., 12 months) may be considered.

Clinical Pearls

• Diagnostic:
  • High index of suspicion: TBM should always be considered in any patient presenting with subacute or chronic meningitis, especially in endemic areas or with risk factors.
  • "Triple test" for TBM: Lymphocytic pleocytosis, low glucose, and high protein in CSF. While supportive, variations occur.
  • Don't wait for culture: Treat empirically if clinical and CSF findings are suggestive. Xpert MTB/RIF is a game-changer for rapid diagnosis.
  • Imaging is key: Especially for assessing hydrocephalus and ruling out other pathologies, even if CSF is inconclusive initially. Basal enhancement is a hallmark.
• Treatment:
  • Early corticosteroids: Start dexamethasone concurrently with anti-TB drugs in all stages; it significantly improves outcomes.
  • Long-duration therapy: TBM requires prolonged anti-TB treatment (9-12 months).
  • Pyridoxine with Isoniazid: Always co-administer to prevent neuropathy.
  • Monitor for IRIS in HIV-coinfected: Worsening symptoms or new lesions after starting ART may indicate IRIS, often managed with corticosteroids.
  • Neurosurgical referral for hydrocephalus: Timely CSF diversion (shunt) can be life-saving.
• Pitfalls:
  • Delayed diagnosis: The most common reason for poor outcomes.
  • Over-reliance on negative AFB smear or culture: These have low sensitivity.
  • Misinterpreting CSF findings: Early TBM may mimic bacterial meningitis with neutrophilic pleocytosis, or viral meningitis with more subtle changes.
  • Inadequate duration of treatment: Leading to relapse and drug resistance.
  • Ignoring drug interactions: Especially with ART in HIV-positive patients.
  • Failure to monitor for adverse drug reactions: Especially hepatotoxicity and optic neuritis.

Recent Updates

• Guidelines:
  • WHO Consolidated Guidelines on Tuberculosis (2020, 2022): Emphasize the role of Xpert MTB/RIF in CSF for rapid diagnosis, standardized regimens for drug-susceptible and drug-resistant TBM, and continued recommendation for adjunctive corticosteroids for all TBM stages.
  • IDSA Guidelines (2016) / CDC Guidelines: Provide comprehensive guidance on TB management, including TBM.
• Evidence:
  • Continued evidence supports the crucial role of adjunctive corticosteroids in reducing mortality and morbidity across all TBM stages.
  • Research into optimal timing of ART initiation in HIV-TBM co-infection suggests starting ART 2-8 weeks after anti-TB therapy initiation, balancing IRIS risk vs. benefits of ART.
  • Ongoing research into host-directed therapies and novel anti-TB drugs for drug-resistant TBM.
• Controversies:
  • Optimal duration of TBM treatment: While 9-12 months is standard, some advocate for longer duration (e.g., 12 months for all stages, or 18-24 months for drug-resistant TBM) based on perceived higher risk of relapse.
  • Role of high-dose rifampicin: Some studies are exploring higher doses of rifampicin to improve CSF penetration, but this is not yet standard clinical practice due to potential toxicity concerns.
  • Treatment of tuberculomas: Whether corticosteroids alone are sufficient or if surgical excision is ever indicated for large, symptomatic tuberculomas. Generally, corticosteroids plus anti-TB therapy lead to resolution.

Key References

• Guidelines:
  • World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Geneva: WHO; 2022. (Key reference for global TB guidelines, including TBM)
  • Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.
• Studies:
  • Thwaites GE, Duc Bang N, Huy Dung N, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct 21;351(17):1741-51. (Landmark study demonstrating benefit of corticosteroids)
  • Heemskerk AD, Bang ND, Mai NTH, et al. Intensified Antituberculosis Therapy and Effects of Adjunctive Dexamethasone in Tuberculous Meningitis: A Prospective, Open-Label, Randomized Controlled Phase 2 Trial. PLoS Med. 2016 Oct 18;13(10):e1002154.
  • Marx FM, Thwaites G. New insights into the management of tuberculous meningitis. Curr Opin Infect Dis. 2018 Jun;31(3):236-241.
• Reviews:
  • Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform approach to diagnosis and management. Lancet Infect Dis. 2010 Oct;10(10):706-17.
  • Chin JH. Tuberculous Meningitis. Semin Neurol. 2019 Jun;39(3):370-376.

---

Disclaimer: This information is provided for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care. Clinical decisions must always be made by a qualified healthcare professional in the context of individual patient circumstances and the latest evidence-based guidelines. Dosages and drug information should be verified with current prescribing information.